BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in developing novel immunotherapies to transform cancer care. The company focuses on cell-based cancer immunotherapies designed to harness and direct the immune system against tumors, with initial emphasis on metastatic breast cancer and other solid tumor indications. BriaCell's lead clinical candidate is Bria-IMT, a targeted immunotherapy currently in Phase 3 clinical trials that has received Fast Track designation from the U.S. Food and Drug Administration for metastatic breast cancer. The company also develops Bria-OTS, a personalized off-the-shelf immunotherapy platform, and is advancing next-generation platforms including Bria-OTS+, with lead candidates Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer. Additionally, BriaCell operates BriaPro Therapeutics Corp., a subsidiary focused on binding agents, proteins, and small-molecule oncology programs designed to enhance the immune system's ability to eliminate tumors. The company operates as a research and development-focused enterprise, advancing multiple immunotherapy modalities through clinical evaluation and regulatory review to improve survival outcomes for cancer patients with limited treatment options.